SCHEMBL1085071

SCHEMBL1085071

Cc1cc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)cc(C)c1C(=O)N1CCC(N2CCCC2CO)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 3/20 0.39
TRPV1 Q8NER1 2/20 0.39
ALDH1A1 P00352 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CHRNB1 P11230 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNB3 Q05901 1/20 0.36
RXRA P19793 2/20 0.36
RXRB P28702 2/20 0.36
RXRG P48443 1/20 0.36
CCR5 P51681 2/20 0.36
TACR3 P29371 1/20 0.36
L3MBTL3 Q96JM7 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TACR2 P21452 1/20 0.36
EPHX2 P34913 1/20 0.35
ENPP2 Q13822 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1083713 1.00 TACR1 (0.39) TACR1TRPV1ALDH1A1MEN1KMT2A
SCHEMBL1085147 0.92 KDM1A (0.41) TRPV1ALDH1A1CHRNB1CHRNB2CHRNB4
SCHEMBL1083711 0.92 KDM1A (0.41) TRPV1ALDH1A1CHRNB1CHRNB2CHRNB4
SCHEMBL1083706 0.91 TRPV1 (0.47) TRPV1ALDH1A1MEN1KMT2ACCR5
SCHEMBL1085174 0.91 TRPV1 (0.47) TRPV1ALDH1A1MEN1KMT2ACCR5
SCHEMBL1083733 0.91 CHRNB1 (0.41) TRPV1ALDH1A1MEN1KMT2ACHRNB1
SCHEMBL1085252 0.91 CHRNB1 (0.41) TRPV1ALDH1A1MEN1KMT2ACHRNB1
SCHEMBL1083692 0.86 TRPV1 (0.39) TACR1TRPV1ALDH1A1MEN1KMT2A
SCHEMBL1085612 0.86 TRPV1 (0.39) TACR1TRPV1ALDH1A1MEN1KMT2A
SCHEMBL1085279 0.84 EPHX2 (0.43) CCR5EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153805-B2 Biaryl derivatives HOFFMANN-LA ROCHE INC. (US) 2012-04-10 US disclosed
EP-2205583-A2 N-HETEROCYCLIC BIARYL CARBOXAMIDES AS CCR RECEPTOR ANTAGONISTS F. Hoffmann-Roche AG (CH) 2010-07-14 EP disclosed
WO-2009043747-A2 N-HETEROCYCLIC BIARYL CARBOXAMIDES AS CCR RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-09 WO disclosed
US-20090048238-A1 NOVEL BIARYL DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048238-A1 NOVEL BIARYL DERIVATIVES CCR3, CCRL2, CCR2 TACR1 188/4885TRPV1 196/4885ALDH1A1 1202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.